Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury

Study objective Rapid hemostasis is crucial in controlling severe extremity hemorrhage. Our objective is to evaluate the hemostatic efficacy of a newly modified amylopectin powder in a model of severe extremity arterial hemorrhage. Methods Anesthetized pigs underwent severe, reproducible femoral art...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of emergency medicine 2009-06, Vol.53 (6), p.804-810
Hauptverfasser: Kilbourne, Michael, MD, Keledjian, Kaspar, MD, Hess, John R., MD, MPH, Scalea, Thomas, MD, Bochicchio, Grant V., MD, MPH
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 810
container_issue 6
container_start_page 804
container_title Annals of emergency medicine
container_volume 53
creator Kilbourne, Michael, MD
Keledjian, Kaspar, MD
Hess, John R., MD, MPH
Scalea, Thomas, MD
Bochicchio, Grant V., MD, MPH
description Study objective Rapid hemostasis is crucial in controlling severe extremity hemorrhage. Our objective is to evaluate the hemostatic efficacy of a newly modified amylopectin powder in a model of severe extremity arterial hemorrhage. Methods Anesthetized pigs underwent severe, reproducible femoral artery injuries. Animals were randomized (nonblinded) to either modified amylopectin powder (n=10) or standard gauze application (n=6). Each hemostatic agent was applied through a pool of blood with manual compression for 3-minute intervals until hemostasis was achieved. Fluid resuscitation was infused as necessary to reestablish a mean arterial pressure within at least 80% of the preinjury mean arterial pressure if possible. The primary measured outcome was total blood loss. Secondary endpoints were survival, time to hemostasis, resuscitation mean arterial pressure, and resuscitation volume. Results Pretreatment blood losses were similar in both groups. Median (absolute average deviation of the median) posttreatment blood loss was significantly less in the modified amylopectin powder group than in the gauze group, 275 (108) mL versus 1,312 (171) mL. Resuscitation mean arterial pressure at 180 minutes after injury was 68% of preinjury mean arterial pressure in the modified amylopectin powder group and undetectable in all control animals. Fluid volume required for resuscitation was 1,962 (258) mL in the modified amylopectin powder group and 2,875 (150) mL in the gauze group. Time to hemostasis was 9.0 (2.1) minutes in the modified amylopectin powder group. Hemostasis was not achieved in any animal in the gauze group. Survival was 100% in the modified amylopectin powder group, whereas no animals survived in the gauze group. Conclusion Modified amylopectin powder demonstrates the ability to control major vascular bleeding in a lethal arterial injury model during a 3-hour period.
doi_str_mv 10.1016/j.annemergmed.2008.12.041
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67264019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196064409000079</els_id><sourcerecordid>67264019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-4a5c52e0209d695fa4090495fae90fbca19dde899a021fe7afa7475d1a723d8f3</originalsourceid><addsrcrecordid>eNqNkkGP1CAUx4nRuOPqVzD1oLfWB6XtcDGZTEZ3kzGaqGfCwkOpLYzQqv320sxkYzzJhRf4_R_kB4S8oFBRoO3rvlLe44jx64imYgDbirIKOH1ANhREV7ZdCw_JBqhoS2g5vyJPUuoBQHBGH5MrKmpGGes2xN3gGNKkJqeLg7VOK70UwRbvg3HWoSl24zKEE-rJ-eJj-GUwFrlSxRGnb2rIS1E7jyuPwxo8_J4ijm5ail2cMLrM3Pp-jstT8siqIeGzy3xNvrw9fN7flMcP7273u2OpeQtTyVWjG4bAQJhWNFZxEMDXAgXYO62oMAa3Qihg1GKnrOp41xiqOlabra2vyatz31MMP2ZMkxxd0jgMymOYk2w71vJsJoPiDOoYUopo5Sm6UcVFUpCrZ9nLvzzL1bOkTGbPOfv8csh8t-7dJy9iM_DyAqik1WCj8tqle47Rpq6FWBvtzxxmJT8dRpm0Q6_RuJilSxPcf13nzT9d9OB8fszhOy6Y-jBHn51LKlMOyE_rx1j_RVabRyfqP5vstzg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67264019</pqid></control><display><type>article</type><title>Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kilbourne, Michael, MD ; Keledjian, Kaspar, MD ; Hess, John R., MD, MPH ; Scalea, Thomas, MD ; Bochicchio, Grant V., MD, MPH</creator><creatorcontrib>Kilbourne, Michael, MD ; Keledjian, Kaspar, MD ; Hess, John R., MD, MPH ; Scalea, Thomas, MD ; Bochicchio, Grant V., MD, MPH</creatorcontrib><description>Study objective Rapid hemostasis is crucial in controlling severe extremity hemorrhage. Our objective is to evaluate the hemostatic efficacy of a newly modified amylopectin powder in a model of severe extremity arterial hemorrhage. Methods Anesthetized pigs underwent severe, reproducible femoral artery injuries. Animals were randomized (nonblinded) to either modified amylopectin powder (n=10) or standard gauze application (n=6). Each hemostatic agent was applied through a pool of blood with manual compression for 3-minute intervals until hemostasis was achieved. Fluid resuscitation was infused as necessary to reestablish a mean arterial pressure within at least 80% of the preinjury mean arterial pressure if possible. The primary measured outcome was total blood loss. Secondary endpoints were survival, time to hemostasis, resuscitation mean arterial pressure, and resuscitation volume. Results Pretreatment blood losses were similar in both groups. Median (absolute average deviation of the median) posttreatment blood loss was significantly less in the modified amylopectin powder group than in the gauze group, 275 (108) mL versus 1,312 (171) mL. Resuscitation mean arterial pressure at 180 minutes after injury was 68% of preinjury mean arterial pressure in the modified amylopectin powder group and undetectable in all control animals. Fluid volume required for resuscitation was 1,962 (258) mL in the modified amylopectin powder group and 2,875 (150) mL in the gauze group. Time to hemostasis was 9.0 (2.1) minutes in the modified amylopectin powder group. Hemostasis was not achieved in any animal in the gauze group. Survival was 100% in the modified amylopectin powder group, whereas no animals survived in the gauze group. Conclusion Modified amylopectin powder demonstrates the ability to control major vascular bleeding in a lethal arterial injury model during a 3-hour period.</description><identifier>ISSN: 0196-0644</identifier><identifier>EISSN: 1097-6760</identifier><identifier>DOI: 10.1016/j.annemergmed.2008.12.041</identifier><identifier>PMID: 19321227</identifier><identifier>CODEN: AEMED3</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Administration, Topical ; Amylopectin - administration &amp; dosage ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Emergency ; Female ; Femoral Artery - injuries ; Fluid Therapy ; Hemorrhage - drug therapy ; Hemostatics - administration &amp; dosage ; Intensive care medicine ; Medical sciences ; Pharmacology. Drug treatments ; Powders ; Sus scrofa</subject><ispartof>Annals of emergency medicine, 2009-06, Vol.53 (6), p.804-810</ispartof><rights>American College of Emergency Physicians</rights><rights>2008 American College of Emergency Physicians</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-4a5c52e0209d695fa4090495fae90fbca19dde899a021fe7afa7475d1a723d8f3</citedby><cites>FETCH-LOGICAL-c460t-4a5c52e0209d695fa4090495fae90fbca19dde899a021fe7afa7475d1a723d8f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.annemergmed.2008.12.041$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21533991$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19321227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kilbourne, Michael, MD</creatorcontrib><creatorcontrib>Keledjian, Kaspar, MD</creatorcontrib><creatorcontrib>Hess, John R., MD, MPH</creatorcontrib><creatorcontrib>Scalea, Thomas, MD</creatorcontrib><creatorcontrib>Bochicchio, Grant V., MD, MPH</creatorcontrib><title>Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury</title><title>Annals of emergency medicine</title><addtitle>Ann Emerg Med</addtitle><description>Study objective Rapid hemostasis is crucial in controlling severe extremity hemorrhage. Our objective is to evaluate the hemostatic efficacy of a newly modified amylopectin powder in a model of severe extremity arterial hemorrhage. Methods Anesthetized pigs underwent severe, reproducible femoral artery injuries. Animals were randomized (nonblinded) to either modified amylopectin powder (n=10) or standard gauze application (n=6). Each hemostatic agent was applied through a pool of blood with manual compression for 3-minute intervals until hemostasis was achieved. Fluid resuscitation was infused as necessary to reestablish a mean arterial pressure within at least 80% of the preinjury mean arterial pressure if possible. The primary measured outcome was total blood loss. Secondary endpoints were survival, time to hemostasis, resuscitation mean arterial pressure, and resuscitation volume. Results Pretreatment blood losses were similar in both groups. Median (absolute average deviation of the median) posttreatment blood loss was significantly less in the modified amylopectin powder group than in the gauze group, 275 (108) mL versus 1,312 (171) mL. Resuscitation mean arterial pressure at 180 minutes after injury was 68% of preinjury mean arterial pressure in the modified amylopectin powder group and undetectable in all control animals. Fluid volume required for resuscitation was 1,962 (258) mL in the modified amylopectin powder group and 2,875 (150) mL in the gauze group. Time to hemostasis was 9.0 (2.1) minutes in the modified amylopectin powder group. Hemostasis was not achieved in any animal in the gauze group. Survival was 100% in the modified amylopectin powder group, whereas no animals survived in the gauze group. Conclusion Modified amylopectin powder demonstrates the ability to control major vascular bleeding in a lethal arterial injury model during a 3-hour period.</description><subject>Administration, Topical</subject><subject>Amylopectin - administration &amp; dosage</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Emergency</subject><subject>Female</subject><subject>Femoral Artery - injuries</subject><subject>Fluid Therapy</subject><subject>Hemorrhage - drug therapy</subject><subject>Hemostatics - administration &amp; dosage</subject><subject>Intensive care medicine</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Powders</subject><subject>Sus scrofa</subject><issn>0196-0644</issn><issn>1097-6760</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkkGP1CAUx4nRuOPqVzD1oLfWB6XtcDGZTEZ3kzGaqGfCwkOpLYzQqv320sxkYzzJhRf4_R_kB4S8oFBRoO3rvlLe44jx64imYgDbirIKOH1ANhREV7ZdCw_JBqhoS2g5vyJPUuoBQHBGH5MrKmpGGes2xN3gGNKkJqeLg7VOK70UwRbvg3HWoSl24zKEE-rJ-eJj-GUwFrlSxRGnb2rIS1E7jyuPwxo8_J4ijm5ail2cMLrM3Pp-jstT8siqIeGzy3xNvrw9fN7flMcP7273u2OpeQtTyVWjG4bAQJhWNFZxEMDXAgXYO62oMAa3Qihg1GKnrOp41xiqOlabra2vyatz31MMP2ZMkxxd0jgMymOYk2w71vJsJoPiDOoYUopo5Sm6UcVFUpCrZ9nLvzzL1bOkTGbPOfv8csh8t-7dJy9iM_DyAqik1WCj8tqle47Rpq6FWBvtzxxmJT8dRpm0Q6_RuJilSxPcf13nzT9d9OB8fszhOy6Y-jBHn51LKlMOyE_rx1j_RVabRyfqP5vstzg</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Kilbourne, Michael, MD</creator><creator>Keledjian, Kaspar, MD</creator><creator>Hess, John R., MD, MPH</creator><creator>Scalea, Thomas, MD</creator><creator>Bochicchio, Grant V., MD, MPH</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090601</creationdate><title>Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury</title><author>Kilbourne, Michael, MD ; Keledjian, Kaspar, MD ; Hess, John R., MD, MPH ; Scalea, Thomas, MD ; Bochicchio, Grant V., MD, MPH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-4a5c52e0209d695fa4090495fae90fbca19dde899a021fe7afa7475d1a723d8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Topical</topic><topic>Amylopectin - administration &amp; dosage</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Emergency</topic><topic>Female</topic><topic>Femoral Artery - injuries</topic><topic>Fluid Therapy</topic><topic>Hemorrhage - drug therapy</topic><topic>Hemostatics - administration &amp; dosage</topic><topic>Intensive care medicine</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Powders</topic><topic>Sus scrofa</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kilbourne, Michael, MD</creatorcontrib><creatorcontrib>Keledjian, Kaspar, MD</creatorcontrib><creatorcontrib>Hess, John R., MD, MPH</creatorcontrib><creatorcontrib>Scalea, Thomas, MD</creatorcontrib><creatorcontrib>Bochicchio, Grant V., MD, MPH</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of emergency medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kilbourne, Michael, MD</au><au>Keledjian, Kaspar, MD</au><au>Hess, John R., MD, MPH</au><au>Scalea, Thomas, MD</au><au>Bochicchio, Grant V., MD, MPH</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury</atitle><jtitle>Annals of emergency medicine</jtitle><addtitle>Ann Emerg Med</addtitle><date>2009-06-01</date><risdate>2009</risdate><volume>53</volume><issue>6</issue><spage>804</spage><epage>810</epage><pages>804-810</pages><issn>0196-0644</issn><eissn>1097-6760</eissn><coden>AEMED3</coden><abstract>Study objective Rapid hemostasis is crucial in controlling severe extremity hemorrhage. Our objective is to evaluate the hemostatic efficacy of a newly modified amylopectin powder in a model of severe extremity arterial hemorrhage. Methods Anesthetized pigs underwent severe, reproducible femoral artery injuries. Animals were randomized (nonblinded) to either modified amylopectin powder (n=10) or standard gauze application (n=6). Each hemostatic agent was applied through a pool of blood with manual compression for 3-minute intervals until hemostasis was achieved. Fluid resuscitation was infused as necessary to reestablish a mean arterial pressure within at least 80% of the preinjury mean arterial pressure if possible. The primary measured outcome was total blood loss. Secondary endpoints were survival, time to hemostasis, resuscitation mean arterial pressure, and resuscitation volume. Results Pretreatment blood losses were similar in both groups. Median (absolute average deviation of the median) posttreatment blood loss was significantly less in the modified amylopectin powder group than in the gauze group, 275 (108) mL versus 1,312 (171) mL. Resuscitation mean arterial pressure at 180 minutes after injury was 68% of preinjury mean arterial pressure in the modified amylopectin powder group and undetectable in all control animals. Fluid volume required for resuscitation was 1,962 (258) mL in the modified amylopectin powder group and 2,875 (150) mL in the gauze group. Time to hemostasis was 9.0 (2.1) minutes in the modified amylopectin powder group. Hemostasis was not achieved in any animal in the gauze group. Survival was 100% in the modified amylopectin powder group, whereas no animals survived in the gauze group. Conclusion Modified amylopectin powder demonstrates the ability to control major vascular bleeding in a lethal arterial injury model during a 3-hour period.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>19321227</pmid><doi>10.1016/j.annemergmed.2008.12.041</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0196-0644
ispartof Annals of emergency medicine, 2009-06, Vol.53 (6), p.804-810
issn 0196-0644
1097-6760
language eng
recordid cdi_proquest_miscellaneous_67264019
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Administration, Topical
Amylopectin - administration & dosage
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Animals
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Emergency
Female
Femoral Artery - injuries
Fluid Therapy
Hemorrhage - drug therapy
Hemostatics - administration & dosage
Intensive care medicine
Medical sciences
Pharmacology. Drug treatments
Powders
Sus scrofa
title Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T21%3A03%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemostatic%20Efficacy%20of%20Modified%20Amylopectin%20Powder%20in%20a%20Lethal%20Porcine%20Model%20of%20Extremity%20Arterial%20Injury&rft.jtitle=Annals%20of%20emergency%20medicine&rft.au=Kilbourne,%20Michael,%20MD&rft.date=2009-06-01&rft.volume=53&rft.issue=6&rft.spage=804&rft.epage=810&rft.pages=804-810&rft.issn=0196-0644&rft.eissn=1097-6760&rft.coden=AEMED3&rft_id=info:doi/10.1016/j.annemergmed.2008.12.041&rft_dat=%3Cproquest_cross%3E67264019%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67264019&rft_id=info:pmid/19321227&rft_els_id=S0196064409000079&rfr_iscdi=true